Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter of 2026 Updated data from MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track for

#PYXS Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

www.stocktitan.net/news/PYXS/pyxis-oncology...

Trade Alerts, Thursday December 18, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Thu Dec 18th - #OCC #JZXN #VMAR #RVYL #PYXS #HOWL #GANX #EVTV #BDRX #AZI #ATON #PSQH #$NMG - More: crystalequityresearch.com/trade-alerts... - #smallcap

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma 46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA ® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kg Updated

#PYXS Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

www.stocktitan.net/news/PYXS/pyxis-oncology...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #XXRP 119% OTM
2. #HIMS 70% OTM
3. #TMC 57% OTM
4. #COIN 55% OTM
5. #PYXS 53% OTM

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #COIN 94% OTM
2. #TMC 57% OTM
3. #PYXS 53% OTM
4. #PLCE 53% OTM
5. #META 50% OTM

#OptionFlow #OptionsTrading #Trading

Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update Pyxis Oncology (Nasdaq: PYXS) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead antibody-drug conjugate (ADC) candidate, micvotabart pelidotin (MICVO), is advancing in clinical trials with preliminary data expected in H2 2025 and H1 2026.Key financial highlights include $90.4 million in cash and investments, providing runway into H2 2026. Q2 revenues were $2.8 million from a milestone payment from Simcere, with a net loss of $18.4 million ($0.30 per share). R&D expenses increased to $17.1 million, while G&A expenses decreased to $5.4 million.The company is progressing with two key clinical trials: a Phase 1 monotherapy study for head and neck cancer and a Phase 1/2 combination study with KEYTRUDA®, both showing promising potential in treating advanced solid tumors.

#PYXS Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PYXS/pyxis-oncology...

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update Pyxis Oncology (NASDAQ: PYXS) reported Q1 2025 financial results and provided updates on its lead candidate micvotabart pelidotin (MICVO). The company presented promising preclinical data demonstrating MICVO's unique three-pronged mechanism of action, showing anti-tumor activity through direct tumor killing, bystander effect, and immunogenic cell death. Key upcoming milestones include preliminary data from Phase 1 trials in H2 2025 for MICVO monotherapy in head and neck cancer patients and combination therapy with pembrolizumab. Financially, Pyxis reported $106.9 million in cash and investments, with runway extending into H2 2026. Q1 2025 saw a net loss of $21.2 million ($0.35 per share), with R&D expenses at $17.0 million and G&A expenses at $5.9 million. The company remains focused on developing treatments for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and other advanced solid tumors.

#PYXS Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/PYXS/pyxis-oncology...

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC Pyxis Oncology (NASDAQ: PYXS) presented promising preclinical results for micvotabart pelidotin (MICVO), their first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin. The data, presented at AACR 2025, demonstrated:45% of PDX models showed strong to very strong tumor growth inhibitionComplete responses were observed across multiple tumor indicationsThe drug was well-tolerated at 3mg/kg dosingCombination therapy with anti-PD-1 achieved 91% tumor growth inhibition with complete response in 9/15 animalsMICVO's three-pronged mechanism of action includes direct tumor killing, bystander effect, and immunogenic cell death. The drug is currently in Phase 1 trials as both monotherapy and in combination with KEYTRUDA for advanced solid tumors.

#PYXS Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

www.stocktitan.net/news/PYXS/pyxis-oncology...

Pyxis Cancer Drug Shows Remarkable 50% Response Rate as FDA Fast-Tracks Development Pyxis advances MICVO cancer therapy with FDA Fast Track status and promising trial results. $128.4M cash runway extends to 2026 while streamlining operations for clinical focus.

#PYXS Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/PYXS/pyxis-oncology...

Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? Pyxis's innovative antibody-drug conjugate targeting EDB+FN receives expedited regulatory pathway for recurrent/metastatic head and neck cancer treatment.

#PYXS Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

www.stocktitan.net/news/PYXS/pyxis-oncology...

Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial Pyxis Oncology launches Phase 1/2 trial combining PYX-201 with Merck's Keytruda for multiple solid tumors, while expanding its Phase 1 monotherapy study for head and neck cancer.

#PYXS Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

www.stocktitan.net/news/PYXS/pyxis-oncology...

Pyxis Oncology's PYX-201 Shows Impressive 50% Response Rate in Cancer Trial, Shifts Focus to Lead Program Promising Phase 1 results for PYX-201 in head and neck cancer lead Pyxis to prioritize development, showing strong efficacy across multiple solid tumor types.

#PYXS Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

www.stocktitan.net/news/PYXS/pyxis-oncology...

#PYXS Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

www.stocktitan.net/news/PYXS/pyxis-oncology...

Just In: ( NASDAQ: #PYXS ) Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

#StockMarket #News